Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide sweeps create ecological units in the human gut microbiome.

Nature·2026
Same author

Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol.

BMJ open·2025
Same author

Ileal Biofilms Confirm SIBO-IBS Hypothesis: Comment on PMID 38798120.

Neurogastroenterology and motility·2025
Same author

An unexpected tumor-resistant phenotype from floxing PAK1 in a mouse model of colitis associated cancer.

Scientific reports·2025
Same author

Filamin A editing in myeloid cells reduces intestinal inflammation and protects from colitis.

The Journal of experimental medicine·2025
Same author

Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.

PloS one·2025
Same journal

Needle-based confocal laser endomicroscopy and artificial intelligence in pancreatic cystic lesions: Insights and clinical advances.

Best practice & research. Clinical gastroenterology·2026
Same journal

Evidence-based approach to the diagnosis, management and surveillance of pancreatic cystic lesions: from the guidelines to the clinical practice.

Best practice & research. Clinical gastroenterology·2026
Same journal

Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound.

Best practice & research. Clinical gastroenterology·2026
Same journal

Predictive risk models for the diagnosis and cancer progression of pancreatic cysts.

Best practice & research. Clinical gastroenterology·2026
Same journal

Preface.

Best practice & research. Clinical gastroenterology·2026
Same journal

Endoscopic ultrasound-guided treatment of pancreatic lesions.

Best practice & research. Clinical gastroenterology·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Murine Colitis Modeling using Dextran Sulfate Sodium (DSS)
08:39

Murine Colitis Modeling using Dextran Sulfate Sodium (DSS)

Published on: January 19, 2010

Aminosalicylates.

Christoph Campregher1, Christoph Gasche

  • 1Christian Doppler Laboratory for Molecular Cancer Chemoprevention, Division of Gastroenterology and Hepatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, Austria.

Best Practice & Research. Clinical Gastroenterology
|November 30, 2011
PubMed
Summary
This summary is machine-generated.

Aminosalicylates are key for inflammatory bowel disease treatment. This review covers their properties for preventing colorectal cancer in ulcerative colitis patients.

Related Experiment Videos

Last Updated: May 27, 2026

Murine Colitis Modeling using Dextran Sulfate Sodium (DSS)
08:39

Murine Colitis Modeling using Dextran Sulfate Sodium (DSS)

Published on: January 19, 2010

Area of Science:

  • Gastroenterology and pharmacology.

Background:

  • Aminosalicylates are primary treatments for inflammatory bowel disease (IBD).
  • Pro-drugs and formulations enhance aminosalicylate bioavailability and efficacy for ulcerative colitis (UC) and Crohn's disease.
  • In vitro and clinical studies confirm aminosalicylates' safety and effectiveness.

Purpose of the Study:

  • To review aminosalicylates' molecular, pharmacological, and clinical aspects.
  • To assess aminosalicylates' potential in chemoprevention of UC-associated colorectal cancer.

Main Methods:

  • Literature review of in vitro and clinical studies.
  • Analysis of aminosalicylate properties related to drug delivery and action.
  • Evaluation of evidence for chemopreventive effects.

Main Results:

  • Aminosalicylates demonstrate established efficacy and safety in IBD treatment.
  • Various formulations aim to optimize drug delivery and therapeutic outcomes.
  • Evidence suggests a role for aminosalicylates in the chemoprevention of colorectal cancer in UC patients.

Conclusions:

  • Aminosalicylates are well-established, safe, and effective for IBD.
  • Optimized formulations improve pharmacological profiles and patient outcomes.
  • Further research into aminosalicylates' chemopreventive potential for UC-associated colorectal cancer is warranted.